Biological variation of cardiac biomarkers in aortic valve stenosis

Completed

• Conditions: Aortic stenosis; calcification of the aortic valve; 10046973

• Registration Number: NL-OMON44121
• Lead Sponsor: Medisch Universitair Ziekenhuis Maastricht

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2017-10-16
• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 25

Inclusion Criteria

Individuals (aged * 18 years) with clinically stable moderate aortic valve stenosis, defined by serial Doppler echocardiographic measurements of maximum transvalvular velocity (Vmax), mean pressure gradient (PGmean), and Aortic Valve Area (AVA) and a preserved ejection fraction (EF), will be recruited to participate in this study. Only subjects who are able to provide informed consent will be included.

Exclusion Criteria

Subjects with severe aortic valve stenosis
Subjects with clinically progressive aortic valve stenosis
Subjects with documented atrial fibrillation in the last year. (subjects are allowed to have a history of atrial fibrillation)
Subjects with acute myocardial infarction in the last 6 months
Subjects with hospitalisation for heart failure in the last 6 months
Subjects with pulmonary embolism in the last 6 months
Subjects with chronic kidney disease (CKD)

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Concentrations of cardiac biomarkers (eg troponins, NT-pro-BNP, ST-2 and<br /><br>galectin-3) measured 7 times within 1 year. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Not applicable.</p><br>